ACHV earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -5.63. Updated 2026-07-23.
Achieve Life Sciences (ACHV) Research Hub
Achieve Life Sciences (ACHV) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.06 USD (-6.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.63, market cap 0.65B. This hub links to the full technical, earnings and options research available for ACHV.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.06 USD (-6.37%) |
| 52-week range | 4.91 USD – 8.64 USD |
| Trend regime | Range |
| 14-day RSI | 54.4 (Neutral) |
| Trailing P/E | -5.63 |
| Market cap | 0.65B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ACHV
Covered Call on ACHV: how it works, illustrative setup around the real 7.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACHV: how it works, illustrative setup around the real 7.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACHV: how it works, illustrative setup around the real 7.06 USD price, max profit/loss, breakeven and when to use it. Educational.
ACHV technical analysis: range, last 7.06 USD, RSI 54.4, 52w range 4.91 USD–8.64 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ACHV in?
Achieve Life Sciences (ACHV) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACHV in an uptrend or downtrend?
As of 2026-09-11, ACHV is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACHV's trailing P/E ratio?
ACHV's trailing P/E is -5.63, with a market cap of 0.65B. See the earnings research page for full valuation detail.
When does ACHV next report earnings?
ACHV is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.18 USD.